Clinical Trial Update: Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating eleclazine for shortening QT interval, safety, and tolerability in adults with Long QT Syndrome Type 3; study terminated with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Qt Syndrome Type 3

Drugs mentioned

• Eleclazine (Eleclazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Long QT Syndrome Type 3 | Phase 3 | Status: TERMINATED | Results posted: 2018-01-12